Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 63 results for dyspepsia

  1. Laparoscopic fundoplication compared with medical management:- What is the effectiveness of laparoscopic fundoplication compared with medical management in people with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    9 June 2015

  2. Patient characteristics, risk factors and predictors that indicate endoscopy for excluding Barrett's oesophagus:- In people who experience symptoms of gastro-oesophageal reflux disease (GORD) or symptoms suggestive of GORD, what patient characteristics, risk factors and predictors indicate when endoscopy is needed to exclude Barrett's oesophagus?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    9 June 2015

  3. Osteoporosis (QS149)

    This quality standard covers managing osteoporosis in adults (aged 18 and over), including assessing risk and preventing fragility fractures. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    28 April 2017
    View quality statements

    Sections for QS149

  4. What is the clinical effectiveness of double-dose PPIs in people with severe erosive reflux disease (Los Angeles classification grade C/D or Savary–Miller grade 3/4): to reduce severe oesophagitis to control symptoms as maintenance therapy?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    15 November 2019

  5. What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    15 November 2019

  6. Effective proton pump inhibitor dosage for severe erosive reflux disease:- What is the clinical effectiveness of double-dose PPIs in people with severe erosive reflux disease (Los Angeles classification grade C/D or Savary–Miller grade 3/4): - to reduce severe oesophagitis - to control symptoms - as maintenance therapy?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    9 June 2015

  7. Other specialist management:- What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

    Research recommendation
    Published
    9 June 2015

  8. Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)

    This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.

    Clinical guideline
    Last updated
    30 November 2016
    View recommendations

    Sections for CG95

  9. Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

    Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

    Technology appraisal guidance
    Published
    6 February 2018
    View recommendations

    Sections for TA504

  10. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

    Evidence summary
    Published
    1 March 2016

  11. Dyspepsia: Management of dyspepsia in adults in primary care (CG17)

    This guidance has been updated and replaced by NICE guideline CG184.

    Clinical guideline
    Published
    25 August 2004

  12. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

    NICE guideline
    Last updated
    13 April 2022
    View recommendations

    Sections for NG128

  13. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.

    Technology appraisal guidance
    Published
    17 December 2014
    View recommendations

    Sections for TA327

  14. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

    Medtech innovation briefing
    Published
    22 May 2015

  15. Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)

    This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.

    NICE guideline
    Published
    6 March 2024
    View recommendations

    Sections for NG239